Linical Co., Ltd.

2183

JP3974530002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
408 ^JPY	+0.25%		+2.26%	-23.02%

Apr. 12	Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	CI
Feb. 21	Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses	MT

Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022

February 14, 2022 at 02:10 am EST

Linical Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2022. For the period, the company expects dividend to be JPY 14 per share.

Latest news about Linical Co., Ltd.

Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Apr. 12	CI
Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses	Feb. 21	MT
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	Feb. 14	CI
Linical Seeks Listing on Standard Market Following Revised Tokyo Stock Exchange Rules	23-09-26	MT
Linical Co., Ltd. Provides Dividend Forecast for the Year Ending March 31, 2024	23-08-14	CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	23-08-14	CI
Linical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-15	CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024	23-05-15	CI
Linical Co., Ltd. Provides Year Ending Dividend Forecast for the Year Ending March 31, 2024	23-05-15	CI
Linical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023	23-05-15	CI
Linical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023	23-02-14	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-14	CI
Linical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023	22-12-27	CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2023	22-12-27	CI
Science 37 Holdings, Linical Americas to Deploy Decentralized Clinical Trial Services	22-11-17	MT
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-11-14	CI
Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index	22-09-19	CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-08-12	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-08-12	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-05-16	CI
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 9, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-05-16	CI
Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	22-02-14	CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	22-02-14	CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2022	21-11-12	CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022	21-11-12	CI

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Linical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

408 JPY

Average target price

500 JPY

Spread / Average Target

+22.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LINICAL CO., LTD.	-23.02%	59.28M
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research

Linical Co., Ltd.

Equities

2183

JP3974530002

Biotechnology & Medical Research

Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022

Latest news about Linical Co., Ltd.

Chart Linical Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Linical Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research